Celecoxib

Celecoxib clinical profile.

Celecoxib is the first COX-2-specific inhibitor approved for relief of the signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA), as well as for treatment of familial adenomatous polyposis. For both OA and RA, celecoxib has been shown to be significantly superior in efficacy to placebo and similar in efficacy to traditional non-steroidal anti-inflammatory drugs. Its advantage,...

Chapter - Iv Celecoxib

Celecoxib-induced cholestatic liver injury

Although drug-induced liver injury is common, physician awareness of specific drug reactions is often limited. Celecoxibinduced drug injury has not been widely reported. We describe the case of a 28 year-old woman who presented to the emergency department with cholestatic liver injury following 13 days of celecoxib use. We searched the literature and reviewed existing case reports of celecoxib-...

Stability of celecoxib oral suspension.

BACKGROUND Celecoxib is a selective cyclo-oxygenase 2 inhibitor that relieves pain without affecting platelet function, causing gastrointestinal toxic effects, or increasing the risk of bleeding. OBJECTIVES To develop a suspension formulation for oral celecoxib and to determine its physical and chemical stability when packaged in amber polyvinyl chloride (PVC) bottles and stored with refriger...

Celecoxib Nanoparticles for Therapeutic Angiogenesis.

Controllable induction of blood vessel formation (angiogenesis) presents an important therapeutic goal in ischemic diseases and is also beneficial in various normal physiological processes. In this study, we have shown that nanoparticles of celecoxib, a lipophilic nonsteroidal anti-inflammatory drug, effectively evoke therapeutic angiogenesis in animal models, in both normal and ischemic organs...